HomeFilePeripheral vascular disease

Peripheral vascular disease

ECS Guidelines for COVID-19 Management

One of the first statements in this document points out these are not “regular guidelines” developed after...

Cardiology in Times of Coronavirus: The Perfect Storm

Since January 2020, the COVID-19 infection has spread from China to the rest of the world. The...

Virtual ACC 2020 | Renal Denervation Arises with New Evidence

In patients with uncontrolled hypertension who do not comply with treatment, renal denervation can generate benefit by...

Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events

In patients with peripheral artery disease undergoing revascularization, the combination of rivaroxaban (Xarelto) and low doses of...

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses...

Is There a Relationship between ARBs, ACE 2 Inhibitors and COVID-19?

In the past few days, many doctors appear to have caught wind of somewhat unfounded data. According...

Cath Lab Management Protocol for the COVID-19 Outbreak

The Interventional Cardiology Association and the Cardiac Beat Association from the Spanish Society of Cardiology have released...

Drug-Coated Balloons in Infrapopliteal Disease: Much Ado About Nothing

The revascularization of tibial arteries in patients with critical lower limb ischemia using drug-coated balloons vs. conventional...